首頁 > 市場調查報告書 > 製藥

非專利藥

市場調查報告書

商品編碼

2050766

非專利無菌注射劑市場：依藥物類型、治療用途、通路和地區分類。

Generic Sterile Injectables Market, by Drug Type, by Therapeutic Application, by Distribution Channel and by Region

出版日期: 2026年04月01日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年，非專利無菌注射劑市場規模估計為514億美元，預計2033年將達到1,047.1億美元。預計2026年至2033年，該市場將以10.7%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	514億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	10.70%	2033年市場規模預測：	1047.1億美元

非專利無菌注射劑是經美國食品藥物管理局(FDA)核准的生物製藥，廣泛應用於醫療保健產業，用於治療多種疾病和病症。非專利無菌注射劑價格遠低於品牌藥，但療效卻與之相當。因此，此類注射劑的需求量一直很高，並被全球絕大多數醫院和診所廣泛使用。然而，由於 FDA 對其生產有嚴格的監管，滿足市場需求仍然是全球非專利無菌注射劑市場主要參與者面臨的持續挑戰。

由於無菌注射劑用途廣泛，可用於治療多種疾病和症狀，預計非專利無菌注射劑市場在不久的將來將保持穩定成長。生產商正致力於擴大非專利無菌注射劑的生產，以滿足不斷成長的市場需求，同時確保產品品質。

市場動態

市場參與者正致力於產品推出新的非專利注射學名藥，預計將加速全球非專利注射學名藥市場在預測期內的成長。例如，2017年6月，百特國際宣布其速效克林黴素注射液（生理食鹽水）獲得美國食品藥物管理局（FDA）核准並上市。本產品有三種常用處方規格（300毫克/50毫升、600毫克/50毫升和900毫克/50毫升）。克林黴素是一種廣泛用於治療由敏感鏈球菌引起的嚴重感染疾病的抗生素，尤其適用於青黴素不適用的患者。

主要企業正著力發展非內生性活動，例如建立合作夥伴關係，預計這將加速預測期內全球非專利注射學名藥市場的成長。例如，2017年，諾華旗下非專利部門山德士投資超過3,354萬美元，用於擴建其位於斯洛維尼亞的抗生素生產設施，以進行設施開發和現代化改造。首條生產線計劃於2021年運作，其他生產線將於2025年前分階段投入使用。

該公司正致力於採取非內部成長策略，例如收購，以擴大其全球業務並增強國際商業機會。例如，2016年8月，梯瓦製藥工業有限公司完成了對艾爾建非專利業務的收購。艾爾建是一家總部位於美國並在愛爾蘭註冊的製藥公司。

本次調查的主要特點

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、區域前景以及主要參與者採取的競爭策略。
本研究根據以下參數對全球非專利無菌注射劑市場的主要參與者進行了分析：公司概況、財務表現、產品系列、地理分佈、分銷策略、關鍵發展和策略以及未來計劃。
透過利用本報告中的見解，企業負責人和經營團隊將能夠就未來的產品發布、技術升級、市場擴張和行銷策略做出明智的決策。
這份全球非專利無菌注射劑市場報告的目標受群眾外包括投資者、供應商、製造商、經銷商、新參與企業和金融分析師等產業相關人員。
相關人員可以透過利用分析全球非專利無菌注射藥物市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 中非
- 北非

第8章競爭情勢

公司簡介
- Baxter International Inc.
- AstraZeneca plc
- Merck & Co., Inc.
- Pfizer Inc.
- Fresenius Kabi
- Novartis International AG
- Teva Pharmaceuticals
- Hikma Pharmaceuticals
- Reddy's Laboratory
- Mylan NV
- Sun Pharmaceutical Industries Ltd.

第9章分析師建議

機會分析
分析師意見
Coherent Opportunity Map

第10章

參考
調查方法

簡介目錄

Product Code: CMI519

Generic Sterile Injectables Market is estimated to be valued at USD 51.40 Bn in 2026 and is expected to reach USD 104.71 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 51.40 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	10.70%	2033 Value Projection:	USD 104.71 Bn

The generic sterile injectable are U.S. FDA approved biologics that are used for the treatment of many diseases and disorders in the vast arena of the healthcare industry. The generic sterile injectable are very inexpensive as compared to that of their branded counterparts of these drugs and performs equally well. Thus, these Injectables are heavily in demand all the time and are used in majority of hospitals and clinics across the globe. However, due to the stringent FDA regulations for the production of these injectable, the rigorous demand satisfaction of these injectable has always been a constant challenge for the key players in the global generic sterile injectable market.

The generic sterile injectable market is expected to gain steady traction in the foreseeable future as the sterile injectable products find its application across a wide number of diseases and medical condition. Manufacturers are focused on increasing the production of generic sterile injectable to meet the rising demands without compromising on the quality of the injectable.

Market Dynamics

Market players are engaged in launching new products for generic sterile injectables, this is expected to increase the growth of the global generic sterile injectables, over the forecast period. For instance, in June 2017, Baxter International Inc. announced the U.S. FDA approval and commercial launch of ready-to-use clindamycin injection in saline in three commonly prescribed formulations (300mg/50mL, 600mg/50mL, and 900mg/50mL). Clindamycin is a widely prescribed antibiotic for serious infections which is caused by susceptible anaerobic bacteria and strains of streptococci, pneumococci and staphylococci, when penicillin is inappropriate for a patient.

Key players are focusing on inorganic activities such as partnerships, this is expected to increase the growth of the global generic sterile injectables market, over the forecast period. For instance, in 2017, Novartis' generic arm Sandoz expanded its antibiotic facility in Slovenia, with an investment of over US$ 33.54 million aimed at the development and modernization of facilities. The first production lines started in 2021, after which new lines will be gradually phased in by 2025.

The company is focused on adopting inorganic growth strategies such as acquisitions to expand its global presence and improve international commercial opportunities. For instance, in August 2016, Teva Pharmaceutical Industries Ltd. completed the acquisition of Allergan's generics business. Allergan plc.is an American, Irish-domiciled pharmaceutical company.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global generic sterile injectables market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Baxter International Inc., AstraZeneca plc, Merck & Co., Inc., Pfizer Inc., Fresenius Kabi, Novartis International AG, Teva Pharmaceuticals, Hikma Pharmaceuticals, Dr. Reddy's Laboratory, Mylan N.V., Sun Pharmaceutical Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global generic sterile injectables market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global generic sterile injectables market

Market Segmentation

By Drug Type (Revenue, USD Bn, 2021 - 2033)
Monoclonal Antibodies
Cytokines
Insulin
Peptide Hormones
Vaccines
Immunoglobulins
Blood Factors
Antibiotics
Others
By Therapeutic Application (Revenue, USD Bn, 2021 - 2033)
Cancer
Metabolic Diseases
Cardiovascular Diseases
Central Nervous System Disease
Infectious Disorders
Musculoskeletal Disorders
Others
By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles
Baxter International Inc.
AstraZeneca plc
Merck & Co., Inc.
Pfizer Inc.
Fresenius Kabi
Novartis International AG
Teva Pharmaceuticals
Hikma Pharmaceuticals
Reddy's Laboratory
Mylan N.V.
Sun Pharmaceutical Industries Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Therapeutic Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Regulatory Scenario
PEST Analysis
Recent Product Launch/Approval
Epidemiology
Mergers and Acquisitions

4. Global Generic Sterile Injectables Market, By Drug Type, 2021-2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Cytokines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Insulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Peptide Hormones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Immunoglobulins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Blood Factors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Generic Sterile Injectables Market, By Therapeutic Application, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Metabolic Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Central Nervous System Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Infectious Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Musculoskeletal Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Generic Sterile Injectables Market, By Distribution Channel, 2021 - 2033 (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Generic Sterile Injectables Market, By Region, 2021 - 2033 (USD Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021 - 2033
- Regional Trends
North America
- Market Size and Forecast, By Drug Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (US$ Bn)
  - U.S.
  - Canada
Latin America
- Market Size and Forecast, By Drug Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Size and Forecast, By Drug Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (US$ Bn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (US$ Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, By Drug Type, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (US$ Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (US$ Bn)
  - South Africa
  - Central Africa
  - North Africa

8. Competitive Landscape

Company Profiles
- Baxter International Inc.
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- AstraZeneca plc
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Merck & Co., Inc.
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Fresenius Kabi
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Novartis International AG
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Teva Pharmaceuticals
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Hikma Pharmaceuticals
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Reddy's Laboratory
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Mylan N.V.
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Sun Pharmaceutical Industries Ltd.
  - Company Overview
  - Drug Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies